Dr. Clarissa Desjardins Ph.D. serves as Independent Director of the Company., with effective 14 November 2019. Since founding Clementia in 2011, Dr. Desjardins has served as the company's Chief Executive Officer. Prior to Clementia, she was Chief Executive Officer and a member of the board of directors at the Centre of Excellence in Personalized Medicine (CEPMED), a Montreal -based federally and privately funded non-profit enterprise created to promote personalized medicine. In 1998, Dr. Desjardins co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was Senior Vice President of Corporate Development and served on the board of directors. Dr. Desjardins also founded Advanced Bioconcept, a research reagent and diagnostics company, in 1992, which was sold to NEN Life Sciences (since acquired by PerkinElmer) in 1998. Dr. Desjardins earned a doctorate in neurology and neurosurgery from McGill University's Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre at McGill University . She currently serves on the Board of Directors for BELLUS Health Inc. Dr. Desjardins has more than 20 years of leadership experience in biotechnology, pharmaceuticals and research. The Board believes that Dr. Desjardins' skills, including her unique experience in the founding of several pharmaceutical and biotechnology companies, leadership roles, corporate development expertise, public company experience and medical education, make her a valuable asset to the Board.
As the Independent Director of Insmed Inc, the total compensation of Clarissa Desjardins at Insmed Inc is $107,346. There are 18 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.
Clarissa Desjardins is 53, he's been the Independent Director of Insmed Inc since 2019. There are 11 older and 10 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.
Clarissa's mailing address filed with the SEC is 700 US HIGHWAY 202/206, , BRIDGEWATER, NJ, 08807.
Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis y Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
Insmed Inc executives and other stock owners filed with the SEC include: